The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | MRD monitoring in patients with R/R B-cell NHL receiving anti-CD19 CAR T-cell therapy.
The advent of CAR-T cell therapy has improved the historically poor outcomes for patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL), however, relapse is still frequent. In this interview, Meryl D. Colton, MD, University of Colorado, Denver, CO, discusses the use of molecular disease monitoring in patients with R/R B-cell NHL receiving anti-CD19 CAR-T cell therapy. The study demonstrated that monitoring cell-free DNA is a sensitive and specific method to detect disease response and relapse. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
